Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection

H. M.C. Shantha Kumara, I. Kirman, D. Feingold, V. Cekic, A. Nasar, T. Arnell, E. Balik, A. Hoffman, R. Baxter, Stephane A Conte, R. L. Whelan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims: Colorectal resection (CR) increases plasma VEGF levels which may promote residual tumor growth. This study assessed the effect of perioperative GMCSF on plasma levels of sVEGFR1, Ang-1 and Ang-2 and also the impact of post-GMCSF plasma on in vitro endothelial cell (EC) growth and invasion. Ang-2 increases while sVEGFR1 and Ang-1 impede angiogenesis. Methods: Fifty-nine CR cancer patients were randomized to 7 perioperative doses of GMCSF or saline for 3 days prior and 4 days after CR. Blood samples were taken pre-drug (PreRx) and on several postoperative days (POD). Protein levels were assessed and PreRx and POD 5 plasma added to EC cultures after which branch point formation (ECBPF) and invasion (ECI) were measured. Results: sVEGFR1 levels were significantly higher on POD 1 and POD 5 in both groups but the GMCSF POD 5 level was twice the control value (p = 0.002). Ang-2 levels were higher on PODs 1 and 5 in both groups (p < 0.05) but the control POD 5 value (vs. GMCSF) was greater (p = 0.03). Ang-1 decreases were noted in all (p = not significant, ns). The control group POD 5 ECBPF was 35.8% greater than Pre Rx (p = 0.001) while the GMCSF result was 18.0% lower (p = ns); the control POD 5 median percent change from baseline was greater than the GMCSF result(p = 0.008). The POD 5 ECI was +12.2% for the control group vs. baseline (p = ns) and -17.2% for the GMCSF group (p = ns): the control median percent change was greater than in the GMCSF group(p = 0.045). Conclusion: CR-related plasma changes are proangiogenic (>Ang-2) and anti-angiogenic (>sVEGFR1); the net effect is promotion of in vitro ECBPF. GMCSF limits the proangiogenic changes (higher POD 5 sVEGFR1 levels and lower Ang-2 elevations, lower POD 5 ECBPF and ECI). The clinical import of these effects is unclear; perioperative GMCSF has anti-angiogenic plasma effects that may limit tumor growth. Further investigation is warranted.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume35
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Blood Proteins
Colorectal Neoplasms
Endothelial Cells
Growth
Residual Neoplasm
Vascular Endothelial Growth Factor A
Cell Culture Techniques
Pharmaceutical Preparations
Neoplasms
Proteins
In Vitro Techniques

Keywords

  • Angiogenesis
  • Angiopoietin-2
  • Colorectal cancer
  • Granulocyte macrophage colony stimulating factor
  • Perioperative anti-cancer therapy
  • sVEGFR-1

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Shantha Kumara, H. M. C., Kirman, I., Feingold, D., Cekic, V., Nasar, A., Arnell, T., ... Whelan, R. L. (2009). Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. European Journal of Surgical Oncology, 35(3), 295-301. https://doi.org/10.1016/j.ejso.2008.07.012

Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. / Shantha Kumara, H. M.C.; Kirman, I.; Feingold, D.; Cekic, V.; Nasar, A.; Arnell, T.; Balik, E.; Hoffman, A.; Baxter, R.; Conte, Stephane A; Whelan, R. L.

In: European Journal of Surgical Oncology, Vol. 35, No. 3, 01.03.2009, p. 295-301.

Research output: Contribution to journalArticle

Shantha Kumara, HMC, Kirman, I, Feingold, D, Cekic, V, Nasar, A, Arnell, T, Balik, E, Hoffman, A, Baxter, R, Conte, SA & Whelan, RL 2009, 'Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection', European Journal of Surgical Oncology, vol. 35, no. 3, pp. 295-301. https://doi.org/10.1016/j.ejso.2008.07.012
Shantha Kumara, H. M.C. ; Kirman, I. ; Feingold, D. ; Cekic, V. ; Nasar, A. ; Arnell, T. ; Balik, E. ; Hoffman, A. ; Baxter, R. ; Conte, Stephane A ; Whelan, R. L. / Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. In: European Journal of Surgical Oncology. 2009 ; Vol. 35, No. 3. pp. 295-301.
@article{1aac8c470ccf49a38d71fae433d40687,
title = "Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection",
abstract = "Aims: Colorectal resection (CR) increases plasma VEGF levels which may promote residual tumor growth. This study assessed the effect of perioperative GMCSF on plasma levels of sVEGFR1, Ang-1 and Ang-2 and also the impact of post-GMCSF plasma on in vitro endothelial cell (EC) growth and invasion. Ang-2 increases while sVEGFR1 and Ang-1 impede angiogenesis. Methods: Fifty-nine CR cancer patients were randomized to 7 perioperative doses of GMCSF or saline for 3 days prior and 4 days after CR. Blood samples were taken pre-drug (PreRx) and on several postoperative days (POD). Protein levels were assessed and PreRx and POD 5 plasma added to EC cultures after which branch point formation (ECBPF) and invasion (ECI) were measured. Results: sVEGFR1 levels were significantly higher on POD 1 and POD 5 in both groups but the GMCSF POD 5 level was twice the control value (p = 0.002). Ang-2 levels were higher on PODs 1 and 5 in both groups (p < 0.05) but the control POD 5 value (vs. GMCSF) was greater (p = 0.03). Ang-1 decreases were noted in all (p = not significant, ns). The control group POD 5 ECBPF was 35.8{\%} greater than Pre Rx (p = 0.001) while the GMCSF result was 18.0{\%} lower (p = ns); the control POD 5 median percent change from baseline was greater than the GMCSF result(p = 0.008). The POD 5 ECI was +12.2{\%} for the control group vs. baseline (p = ns) and -17.2{\%} for the GMCSF group (p = ns): the control median percent change was greater than in the GMCSF group(p = 0.045). Conclusion: CR-related plasma changes are proangiogenic (>Ang-2) and anti-angiogenic (>sVEGFR1); the net effect is promotion of in vitro ECBPF. GMCSF limits the proangiogenic changes (higher POD 5 sVEGFR1 levels and lower Ang-2 elevations, lower POD 5 ECBPF and ECI). The clinical import of these effects is unclear; perioperative GMCSF has anti-angiogenic plasma effects that may limit tumor growth. Further investigation is warranted.",
keywords = "Angiogenesis, Angiopoietin-2, Colorectal cancer, Granulocyte macrophage colony stimulating factor, Perioperative anti-cancer therapy, sVEGFR-1",
author = "{Shantha Kumara}, {H. M.C.} and I. Kirman and D. Feingold and V. Cekic and A. Nasar and T. Arnell and E. Balik and A. Hoffman and R. Baxter and Conte, {Stephane A} and Whelan, {R. L.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1016/j.ejso.2008.07.012",
language = "English (US)",
volume = "35",
pages = "295--301",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection

AU - Shantha Kumara, H. M.C.

AU - Kirman, I.

AU - Feingold, D.

AU - Cekic, V.

AU - Nasar, A.

AU - Arnell, T.

AU - Balik, E.

AU - Hoffman, A.

AU - Baxter, R.

AU - Conte, Stephane A

AU - Whelan, R. L.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Aims: Colorectal resection (CR) increases plasma VEGF levels which may promote residual tumor growth. This study assessed the effect of perioperative GMCSF on plasma levels of sVEGFR1, Ang-1 and Ang-2 and also the impact of post-GMCSF plasma on in vitro endothelial cell (EC) growth and invasion. Ang-2 increases while sVEGFR1 and Ang-1 impede angiogenesis. Methods: Fifty-nine CR cancer patients were randomized to 7 perioperative doses of GMCSF or saline for 3 days prior and 4 days after CR. Blood samples were taken pre-drug (PreRx) and on several postoperative days (POD). Protein levels were assessed and PreRx and POD 5 plasma added to EC cultures after which branch point formation (ECBPF) and invasion (ECI) were measured. Results: sVEGFR1 levels were significantly higher on POD 1 and POD 5 in both groups but the GMCSF POD 5 level was twice the control value (p = 0.002). Ang-2 levels were higher on PODs 1 and 5 in both groups (p < 0.05) but the control POD 5 value (vs. GMCSF) was greater (p = 0.03). Ang-1 decreases were noted in all (p = not significant, ns). The control group POD 5 ECBPF was 35.8% greater than Pre Rx (p = 0.001) while the GMCSF result was 18.0% lower (p = ns); the control POD 5 median percent change from baseline was greater than the GMCSF result(p = 0.008). The POD 5 ECI was +12.2% for the control group vs. baseline (p = ns) and -17.2% for the GMCSF group (p = ns): the control median percent change was greater than in the GMCSF group(p = 0.045). Conclusion: CR-related plasma changes are proangiogenic (>Ang-2) and anti-angiogenic (>sVEGFR1); the net effect is promotion of in vitro ECBPF. GMCSF limits the proangiogenic changes (higher POD 5 sVEGFR1 levels and lower Ang-2 elevations, lower POD 5 ECBPF and ECI). The clinical import of these effects is unclear; perioperative GMCSF has anti-angiogenic plasma effects that may limit tumor growth. Further investigation is warranted.

AB - Aims: Colorectal resection (CR) increases plasma VEGF levels which may promote residual tumor growth. This study assessed the effect of perioperative GMCSF on plasma levels of sVEGFR1, Ang-1 and Ang-2 and also the impact of post-GMCSF plasma on in vitro endothelial cell (EC) growth and invasion. Ang-2 increases while sVEGFR1 and Ang-1 impede angiogenesis. Methods: Fifty-nine CR cancer patients were randomized to 7 perioperative doses of GMCSF or saline for 3 days prior and 4 days after CR. Blood samples were taken pre-drug (PreRx) and on several postoperative days (POD). Protein levels were assessed and PreRx and POD 5 plasma added to EC cultures after which branch point formation (ECBPF) and invasion (ECI) were measured. Results: sVEGFR1 levels were significantly higher on POD 1 and POD 5 in both groups but the GMCSF POD 5 level was twice the control value (p = 0.002). Ang-2 levels were higher on PODs 1 and 5 in both groups (p < 0.05) but the control POD 5 value (vs. GMCSF) was greater (p = 0.03). Ang-1 decreases were noted in all (p = not significant, ns). The control group POD 5 ECBPF was 35.8% greater than Pre Rx (p = 0.001) while the GMCSF result was 18.0% lower (p = ns); the control POD 5 median percent change from baseline was greater than the GMCSF result(p = 0.008). The POD 5 ECI was +12.2% for the control group vs. baseline (p = ns) and -17.2% for the GMCSF group (p = ns): the control median percent change was greater than in the GMCSF group(p = 0.045). Conclusion: CR-related plasma changes are proangiogenic (>Ang-2) and anti-angiogenic (>sVEGFR1); the net effect is promotion of in vitro ECBPF. GMCSF limits the proangiogenic changes (higher POD 5 sVEGFR1 levels and lower Ang-2 elevations, lower POD 5 ECBPF and ECI). The clinical import of these effects is unclear; perioperative GMCSF has anti-angiogenic plasma effects that may limit tumor growth. Further investigation is warranted.

KW - Angiogenesis

KW - Angiopoietin-2

KW - Colorectal cancer

KW - Granulocyte macrophage colony stimulating factor

KW - Perioperative anti-cancer therapy

KW - sVEGFR-1

UR - http://www.scopus.com/inward/record.url?scp=59849114188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849114188&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2008.07.012

DO - 10.1016/j.ejso.2008.07.012

M3 - Article

VL - 35

SP - 295

EP - 301

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 3

ER -